title: [Chemotherapy of advanced non small cell lung cancer: effect on survival and symptoms affecting quality of life].
abstract: BACKGROUND
  The study presents treatment results of 168 patients with non small cell lung cancer in stage IIIB and IV treated since year 2002 to 2006 in Oncological Center in Cracow.
  
  
  METHODS
  Four regimens of chemotherapy: EP (cisplatin, vepesid), MVP (mitomycin C, vinblastin, cisplatin), PN (cisplatin,vinorelbin) and PG (cisplatin, gemcytabin) were used.
  
  
  RESULTS
  Average survival time in group treated with MVP regimen was 7,8 months (median 4,3 months), PG 7,1 months (median 7,3 months), EP 10,2 months (median 7,5 months), PN 14,1 months (median 9,8 months). Differences in median survival time were not significant. Average time to progression in group treated with MVP regimen was 3,5 months (median 2,6 months), PG 5,2 months (median 5,8 months): EP 6,6 months (median 5,2 months), PN 6,7 months (median 5,6 months). Improvement in control of symptoms regarding dyspnea, pain and cough was reached in 60%, 38,7% and 60% of patients respectively. There were no significant differences between chemotherapy regimens regarding improvement in symptoms control.
  
  
  CONCLUSIONS
  Cisplatin + vinorelbin regimen can be recommended as standard method because of the best treatment results.
authors: Klinika Nowotworów Układowych i Uogólnionych Centrum Onkologii, Oddział w Krakowie, ul. Garncarska 11, 31-115 Kraków, Poland.
authors: Janusz
authors: J
authors: Rolski
authors: Tomasz
authors: T
authors: Zemełka
authors: Marek
authors: M
authors: Jasiówka
authors: Grzegorz
authors: G
authors: Czyzewicz
authors: Ewelina
authors: E
authors: Kojs-Pasińska
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D018450:Disease Progression; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009367:Neoplasm Staging; D011044:Poland; D011788:Quality of Life; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D016685:Mitomycin; D014747:Vinblastine; D005047:Etoposide; D016190:Carboplatin; D002945:Cisplatin